Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06363825
Status:
RECRUITING
Last Update Posted:
2024-04-17
First Post:
2024-04-09
Brief Title:
A Study of TAEHAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
Sponsor:
Fujian Medical University
Organization:
Fujian Medical University
Study Overview
Official Title:
Single-arm Prospective Clinical Study of TAEHAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma With High Tumor Load
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy and safety of TAEHAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load
Detailed Description:
At present there are no prospective clinical studies using the combination regimen TAEHAIC Apatinib camrelizumab in the treatment of advanced liver cancer Therefore in this study investigators designed a single-arm prospective multicenter phase Ⅱ clinical study of arterial infusion of TAEHAIC Apatinib camrelizumab in the treatment of advanced liver cancer with high tumor load to explore the safety and efficacy of this regimen If study gets positive results it will provide a reference for the subsequent phase Ⅲ clinical trial design which is expected to provide a new effective approach for the treatment of advanced liver cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None